Oncology CRO Market Shifts Toward Personalized Models With Charles River Laboratories' Launch Of Oncomouse Platform Trend: A Crucial Influence on the Oncology Based In-Vivo CRO Market's Transformation in 2025

What industry-specific factors are fueling the growth of the oncology based in-vivo cro market?
The increase in cancer cases is projected to fuel the expansion of the oncology-centered in-vivo CRO industry in the future. Cancer is a collection of diseases where irregular cells multiply wildly, exceed their typical boundaries, originate in virtually any organ or tissue, and disseminate to other body parts via the blood and lymph systems. The discovery and treatment of cancer necessitate novel drugs and technology, which are subject to various preclinical experiments, clinical studies, and regulatory procedures before being introduced to the public. An oncology in-vivo-based CRO is an organization contracted by a parent company to offer research services such as conducting all or partial aspects of a preclinical in-vivo evaluation (testing with living entities such as animals, plants, or entire cells) prior to the drug or device being tested on humans. As cancer cases rise, so does the demand for inventive treatments and therapies, propelling the oncology-focused in-vivo CRO industry's advancement. For example, according to the American Cancer Society, a non-profit organization based in the US, there were about 609,000 cancer-related fatalities and 1.9 million newly diagnosed cancer cases in the country in 2022. Approximately 620,000 cancer deaths are predicted, suggesting a minor increase in mortality rates in 2024. The increasing incidence of cancer is propelling the oncology-oriented in-vitro CRO industry's progress.

Get Your Oncology Based In-Vivo CRO Market Report Here:
https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Is the projected market size and growth rate for the oncology based in-vivo cro market?
The market size of the Oncology-focused in-vivo CRO has seen robust growth in the past few years. It is projected to expand from $1.39 billion in 2024 to $1.5 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.0%. The historic growth rate is due to several factors including a growing concentration on cancer therapeutics, an escalating incidence of cancer cases, a move towards personalized treatment, growth in the pharmaceutical sector, and demand for therapies specific to individual targets.

The in-vivo CRO market focused on oncology is projected to experience swift expansion in the upcoming years, ballooning to a sum of $2.28 billion by 2029 with a compound annual growth rate (CAGR) of 10.9%. This surge during the predicted timeframe can be credited to the rise of fresh market opportunities, an inclination towards immuno-oncology treatments, an increase in oncology-related clinical trials, precision and targeted treatment methods. Dominant trends for the foreseeable future comprise regenerative therapies and cell treatments, demand for expedited drug creation, the growth of digitization and data analytics, emphasis on the tumor microenvironment, and the escalation in biologics and immunotherapies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What new trends are reshaping the oncology based in-vivo cro market and its opportunities?
Dominant entities in the in vivo CRO market for oncology are concentrating on personalized cancer models to secure the edge over competitors. These personalized models make use of patient-derived xenografts (PDXs) to devise customized treatment plans, increasing the value and effectiveness of preclinical trials. For example, Charles River Laboratories, an American life sciences firm, introduced its OncoMouse platform in 2022, incorporating PDX tech for improved tumor modeling. This platform provides capabilities for high-throughput screening and real-time tracking of tumor development, enabling expedited evaluation of treatment responses. Furthermore, it comes with built-in data analytics that aid in refining treatment procedures based on the unique patient profiles. These developments mark a profound transition towards more efficient and patient-focused methods in oncology research.

What major market segments define the scope and growth of the oncology based in-vivo cro market?
The oncology based in-vivo cro market covered in this report is segmented -

1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Hospitals, Rehabilitation Centers

Subsegments:
1) By Blood Cancer: Leukemia, Lymphoma, Myeloma
2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors
3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

Which region dominates the oncology based in-vivo cro market?
North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the oncology based in-vivo cro industry growth?
Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What Is Covered In The Oncology Based In-Vivo CRO Global Market Report?

• Market Size Forecast: Examine the oncology based in-vivo cro market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the oncology based in-vivo cro market for a structured understanding.
• Key Players Overview: Analyze major players in the oncology based in-vivo cro market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the oncology based in-vivo cro market.
• Segment Contributions: Evaluate how different segments drive overall growth in the oncology based in-vivo cro market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the oncology based in-vivo cro market.
• Industry Challenges: Identify potential risks and obstacles affecting the oncology based in-vivo cro market.
• Competitive Landscape: Review strategic developments in the oncology based in-vivo cro market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.